Evolving Evidence Reviews

Evolving Evidence Reviews are designed to help clients develop policies and manage prior authorizations. Evolving Evidence Reviews are useful when a technology moves beyond emerging but the literature is not mature enough for a full Health Technology Assessment. Evolving Evidence Reviews provide a full-text appraisal of clinical studies, systematic reviews, and clinical practice guidelines as they relate to a specific health technology. Evolving Evidence Reviews provide Levels of Support indicated by these types of evidence. They also provide information on regulatory status, payer policies, and Hayes Insights.

Prolastin-C (Grifols Therapeutics Inc.) Compared With Other Augmentation Therapies for Management of Patients With Alpha-1 Antitrypsin Deficiency and Lung Disease

This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of alpha-1 antitrypsin (AAT) augmentation therapy with Prolastin or Prolastin-C over other alpha-1 proteinase inhibitors (A1PIs), for management of lung disease in patients with AAT deficiency (AATD).

ApiFix (ApiFix Ltd.) for Treatment of Adolescent Idiopathic Scoliosis

This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the currently available design of the ApiFix (ApiFix Ltd.) minimally invasive deformity correction system for spinal curvature correction in the treatment of adolescent idiopathic scoliosis.